Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

11.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein Kinase D2 Regulates GRASP65 Phosphorylation and Golgi Ribbon Unlinking During G2/M Transition.

Cells·2026
Same author

Shp1 phosphatase regulates CXCR2 protein stability and IL8-mediated invasiveness in breast cancer.

Cell death & disease·2026
Same author

<i>CMTM8</i> variants influence BNT162b2 COVID-19 vaccination response by regulating granulocytic/polymorphonuclear myeloid-derived suppressor cell activity.

Frontiers in immunology·2026
Same author

Improving our understanding of the biology of aging: findings from the Age-It Research Program.

The journals of gerontology. Series B, Psychological sciences and social sciences·2025
Same author

Development and characterization of a membrane-permeant GRASP65-mimetic peptide that inhibits Golgi unlinking and cell cycle progression.

Methods (San Diego, Calif.)·2025
Same author

Mono-ADP-ribosylating PARP enzymes in cellular signaling and disease.

Journal of cell science·2025
Same journal

Explainable incremental-value analysis of apparent diffusion coefficient and arterial spin labeling radiomics for ATRX status prediction in glioblastoma.

Frontiers in oncology·2026
Same journal

Study-level factors associated with hematoma after ultrasound-guided vacuum-assisted breast lesion excision: a systematic review and meta-analysis using a T-P-B framework.

Frontiers in oncology·2026
Same journal

Feasibility and strategy analysis of radiotherapy consolidation following immunotherapy for stage IV esophageal squamous cell carcinoma.

Frontiers in oncology·2026
Same journal

Anastomosing hemangioma of the kidney: a case report.

Frontiers in oncology·2026
Same journal

Machine learning-based prediction of prolonged air leak after uniportal video-assisted thoracic surgery segmentectomy.

Frontiers in oncology·2026
Same journal

Past present and future of radiosensitization in cervical cancer.

Frontiers in oncology·2026
See all related articles

Related Experiment Video

Updated: Dec 17, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.5K

Shp1 in Solid Cancers and Their Therapy.

Alessia Varone1, Daniela Spano1, Daniela Corda1,2

  • 1Institute of Biochemistry and Cell Biology, National Research Council, Naples, Italy.

Frontiers in Oncology
|June 30, 2020
PubMed
Summary
This summary is machine-generated.

The tyrosine phosphatase Shp1 acts as a tumor suppressor by regulating cell signaling. Altered Shp1 function or expression contributes to cancer, highlighting its potential as a therapeutic target.

Keywords:
Shp1TCGAcancercancer therapysignalingtyrosine phosphatase

More Related Videos

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

620
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.6K

Related Experiment Videos

Last Updated: Dec 17, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.5K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

620
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.6K

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Shp1 (tyrosine phosphatase) regulates cellular functions and signal transduction.
  • Initially studied in hematopoietic cells, Shp1's role in other tissues and cancer is increasingly recognized.
  • Shp1 acts as a tumor suppressor by inhibiting cancer hallmarks like proliferation and migration.

Purpose of the Study:

  • To review Shp1's functions in non-hematopoietic tissues and solid tumors.
  • To discuss mechanisms regulating Shp1 expression and its role in cancer.
  • To evaluate Shp1 as a potential cancer therapeutic target, including TCGA data analysis.

Main Methods:

  • Literature review of Shp1's cellular functions and cancer relevance.
  • Analysis of mechanisms controlling Shp1 expression.
  • Examination of Shp1 mutations and expression status in various cancers.
  • Bioinformatic analysis of TCGA data for Shp1 genomic alterations and patient survival correlation.

Main Results:

  • Shp1 attenuates signaling pathways crucial for cancer cell proliferation, survival, migration, and invasion.
  • Mutations or epigenetic silencing of Shp1 disrupt homeostatic maintenance, contributing to cancer development.
  • TCGA data analysis provides insights into Shp1 genomic alterations and their impact on survival in solid tumors.

Conclusions:

  • Shp1 plays a critical role in suppressing tumor development and progression across various cancers.
  • Dysregulation of Shp1 function or expression is implicated in human diseases, particularly cancer.
  • Targeting Shp1 presents a promising therapeutic strategy for cancer treatment.